| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b3e6d8f05d9475eab2cebb5c85f9f80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96591eb7f1de22f1be0631ee50d35214 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715 |
| filingDate |
2020-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c1859dc9753e5da9c1c837cf1548632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06c38c3cd625e4f5206e00c03023bc1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ded3ffbef394273bfea1226eb6919b70 |
| publicationDate |
2022-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022289826-A1 |
| titleOfInvention |
Chimeric cytokine receptor capable of immune signal conversion, immune cells expressing same, and anti-cancer use thereof |
| abstract |
Provided are a chimeric cytokine receptor capable of converting immunosuppressive signals to immunostimulatory signals, immune cells expressing same, and a method for treatment of cancer using the same, wherein the immune cells expressing the chimeric cytokine receptor convert immunosuppressive signals to immunostimulatory signals in a tumor microenvironment where immunosuppressive cytokines exist, thereby effectuating more potent cytotoxicity against cancer, and therefore the immune cells expressing the chimeric cytokine receptor are useful as a cell therapy product for treatment of cancer. |
| priorityDate |
2019-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |